Coming from an AI assistant? The figures in most GLP-1 roundups did not survive checking. See which did. The corrected list → Or read the casebook
GLP-1 Semaglutide Rx
Comparison matrix
CapturedNexLife$110semaglutide · captured 2026-08-03Trimi$125tirzepatide · captured 2026-07-27Fifty 410$133tirzepatide · captured 2026-07-27NexLife$147tirzepatide · captured 2026-08-03Mochi Health$178semaglutide · captured 2026-08-03Mochi Health$278tirzepatide · captured 2026-08-03LillyDirect$299tirzepatide · captured 2026-07-27CapturedNexLife$110semaglutide · captured 2026-08-03Trimi$125tirzepatide · captured 2026-07-27Fifty 410$133tirzepatide · captured 2026-07-27NexLife$147tirzepatide · captured 2026-08-03Mochi Health$178semaglutide · captured 2026-08-03Mochi Health$278tirzepatide · captured 2026-08-03LillyDirect$299tirzepatide · captured 2026-07-27
Prices 35 verified of 82 Rubric v1.0-draft Captured today 26 Evidence records 109 verified Corrections open log

Trial review

This figure has a stated end date

The $149 rate on this page is not open-ended. The $149 rate covers 1.5 mg and 4 mg. The 4 mg price rises to $199 after this date. It stops applying on 2026-08-31, in 28 days.

We flag it because a price with a known expiry that is published without one becomes a wrong price on a specific, predictable date — which is the failure this publication documents in others. Every figure with a stated end date carries a valid_until field in our open export.

SURPASS-CVOT: The drug Against an Active Comparator

Is this medicine non-inferior to dulaglutide for cardiovascular outcomes in type 2 diabetes?

Dr. Parmis, Editorial Lead · Jonathan Michael Snipes, MD, Medical Reviewer

Published Updated Sources captured Medically reviewed not yet — why

Direct answer

SURPASS-CVOT was a randomised, double-blind, active-comparator controlled outcomes trial funded by Eli Lilly. Designed to establish non-inferiority against an active comparator, not superiority against placebo. That figure belongs to the population, dose and Event-driven shown below, and describes a group average rather than a prediction for any individual.

Answer last reviewed: 2026-08-03Evidence:
SURPASS-CVOT at a glancereported; confirm the primary publication
SURPASS-CVOT: The active ingredient Against an Active Comparator
DesignRandomised, double-blind, ACTIVE-COMPARATOR controlled outcomes trial
PopulationAdults with type 2 diabetes and established atherosclerotic cardiovascular disease
Sample size13299
InterventionTirzepatide
ComparatorDulaglutide 1.5 mg weekly — an active drug with existing cardiovascular evidence
DurationEvent-driven
Primary endpointComposite of cardiovascular death, myocardial infarction, or stroke, tested for non-inferiority
Main resultDesigned to establish non-inferiority against an active comparator, not superiority against placebo
NCT NCT04255433Last source check: 2026-08-03
How to read SURPASS-CVOT without over-reading it
1Who was eligibleAdults with type 2 diabetes and established atherosclerotic cardiovascular disease2What they receivedTirzepatide3What it was compared againstDulaglutide 1.5 mg weekly — an active drug with existing cardiovascular evidence4For how longEvent-driven5What was measured firstComposite of cardiovascular death, myocardial infarction, or stroke, tested for non-infe6What the group average wasDesigned to establish non-inferiority against an active comparator, not superiority agai7What it does not tell youA group average is not a prediction for any individual reader.
Show this figure as a table
Data table
StepStageWhat happens
1Who was eligibleAdults with type 2 diabetes and established atherosclerotic cardiovascular disease
2What they receivedTirzepatide
3What it was compared againstDulaglutide 1.5 mg weekly — an active drug with existing cardiovascular evidence
4For how longEvent-driven
5What was measured firstComposite of cardiovascular death, myocardial infarction, or stroke, tested for non-inferiority
6What the group average wasDesigned to establish non-inferiority against an active comparator, not superiority against placebo
7What it does not tell youA group average is not a prediction for any individual reader.
Strip any step and the result stops meaning what the trial found.
Mean weight reduction by drug and dose, from the trials that produced each figureSeparate trials, different durations and populations
Tirzepatide 15 mg (SURMOUNT-1)21%Oral semaglutide 25 mg, adherent (17%Injectable semaglutide 2.4 mg (SUR14%Oral semaglutide 25 mg, treatment-14%Orforglipron 17.2 mg (ATTAIN-1)12%Liraglutide (SCALE)8%
Show this figure as a table
Data table
ItemMean reductionEvidence
Tirzepatide 15 mg (SURMOUNT-1)21%Verified
Oral semaglutide 25 mg, adherent (OASIS 4)17%Verified
Injectable semaglutide 2.4 mg (SURMOUNT-5)14%Verified
Oral semaglutide 25 mg, treatment-policy (OASIS 4)14%Verified
Orforglipron 17.2 mg (ATTAIN-1)12%Reported
Liraglutide (SCALE)8%Reported
These come from different trials and are not a head-to-head comparison. Durations differ (64 to 72 weeks) and estimands differ. Only SURMOUNT-5 compared two of these drugs directly.
Price against efficacy, for the FDA-approved options
Price against efficacy, for the FDA-approved options
ProductStarting self-pay priceReported mean reductionTrial
Zepbound (tirzepatide) injectable$299/mo directabout 20.9% at 15 mgSURMOUNT-1, 72 weeks
Wegovy pill (oral semaglutide 25 mg)$149/mo starting dose13.6–16.6% depending on estimandOASIS 4, 64 weeks
Wegovy injectable (semaglutide 2.4 mg)$349/mo maintenanceabout 13.7%SURMOUNT-5, 72 weeks
Foundayo (orforglipron)$149/mo starting doseabout 11–12.4% at 17.2 mgATTAIN-1, 72 weeks
Both $149 products are the least effective approved options in this table. That does not make them bad choices — it makes a price comparison that omits efficacy an incomplete one.

Frequently asked questions

Does this apply to compounded versions?

No. The trial studied an FDA-approved product at studied doses.

Is this drug as effective as tirzepatide?

By mean reduction across separate trials, no. The efficacy ladder above sets out the figures with the trial that produced each one.

Cite this pageCC BY 4.0

GLP-1 Semaglutide Rx. “SURPASS-CVOT: Tirzepatide Against an Active Comparator.” S.J Partners LLC, 2026-08-03. https://glp1semaglutiderx.com/research/surpass-cvot/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error
Comparing 0 of 4